Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:41:17.801Z.
Consensus retrieved: 2026-10-06T10:50:52.889Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:41:17.801Z.
Quote observation: 2026-10-06T19:40:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
Forward PE Ratio (N/A) = Dated Quote Price ($8.15) / Consensus Forward EPS ($-0.77)
FORWARD PE RATIO
N/A
DiaMedica Therapeutics Inc.
Market Cap
$439.31M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $439.31M | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | N/A |
| NeuroPace, Inc. (NPCE)vs › | $435.72M | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $446.85M | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $449.45M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $428.08M | 91.17 |
| NRC Health (NRC)vs › | $454.11M | 22.90 |
| Tilray Brands, Inc. (TLRY)vs › | $424.40M | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $423.92M | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.75M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.15, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.77 | $-0.81 – $-0.73 | 3 | n/m |
| 2027-12-31 | $-0.75 | $-0.90 – $-0.59 | 4 | n/m |
| 2028-12-31 | $-0.93 | $-1.14 – $-0.55 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
